Regeneron lists vonsetamig as available under compassionate use program
Regeneron's expanded access listing shows vonsetamig available for patients through individual patient IND requests.
Regeneron posted one expanded access entry this week for its bispecific antibody vonsetamig.
- Vonsetamig (also known as REGN5459) is listed as an expanded access program with an overall status of available.1 The listing covers plasma cell mediated and antibody mediated conditions.1 Access is limited: compassionate use requests are only being considered in response to Individual Patient Investigational New Drug (IND) applications.1 Eligibility for the program has not been fixed in advance, since eligibility will be determined during the application review process.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.